Damora Therapeutics, Inc. Common Stock (DMRA) Stock Price, News & Analysis

Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Key Stats

• Today's Range: $20.20 to $21.25
• 50-Day Range: $20.23 to $32.44
• 52-Week Range: $3.50 to $38.33
• Volume: 354,631 shs
• Average Volume: 793,275 shs
• Market Capitalization: $1.25 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.50
• Consensus Rating: Buy

Damora Therapeutics, Inc. Common Stock Stock Analysis - MarketRank™

Damora Therapeutics, Inc. Common Stock scored higher than 71% of companies evaluated by MarketBeat, and ranked 226th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Damora Therapeutics, Inc. Common Stock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Damora Therapeutics, Inc. Common Stock has a consensus price target of $46.50, representing about 129.9% upside from its current price of $20.23.

Amount of Analyst Coverage

Damora Therapeutics, Inc. Common Stock has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Damora Therapeutics, Inc. Common Stock are expected to decrease in the coming year, from ($2.06) to ($2.14) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.70% of the float of Damora Therapeutics, Inc. Common Stock has been sold short.

Short Interest Ratio / Days to Cover

Damora Therapeutics, Inc. Common Stock has a short interest ratio ("days to cover") of 8.56.

Change versus previous month

Short interest in Damora Therapeutics, Inc. Common Stock has recently increased by 14.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Damora Therapeutics, Inc. Common Stock does not currently pay a dividend.

Dividend Growth

Damora Therapeutics, Inc. Common Stock does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.91

News Sentiment

Damora Therapeutics, Inc. Common Stock has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Damora Therapeutics, Inc. Common Stock this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for DMRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Damora Therapeutics, Inc. Common Stock to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $245,530.00 in company stock, which represents 0.0197% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Damora Therapeutics, Inc. Common Stock insiders have bought 3,342.82% more of their company's stock than they have sold. Specifically, they have bought $252,875.00 in company stock and sold $7,345.00 in company stock.

Percentage Held by Insiders

0.40% of the stock of Damora Therapeutics, Inc. Common Stock is held by insiders.

Percentage Held by Institutions

14.20% of the stock of Damora Therapeutics, Inc. Common Stock is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DMRA
• Previous Symbol: NASDAQ:GLTO
• CIK: 1800315
• Web: galecto.com
• Phone: 45-7070-5210
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Damora Therapeutics, Inc. Common Stock: $46.50
• High Price Target: $60.00
• Low Price Target: $40.00
• Potential Upside/Downside: +129.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$209.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -176.39%
• Return on Assets: -77.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.73
• Quick Ratio: 19.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($110.11) per share
• Price / Book: -0.18

Miscellaneous

• Outstanding Shares: 61,740,000
• Free Float: 61,489,000
• Market Cap: $1.25 billion
• Optionable: No Data
• Beta: 1.43